<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eight patients with aneurysmal <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> (SAH) received intrathecal <z:chebi fb="0" ids="29321">sodium nitroprusside</z:chebi> therapy (ITSNPT) in the form of intermittent bolus doses for delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after undergoing clipping of an <z:hpo ids='HP_0002617'>aneurysm</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Five patients were administered ITSNPT to combat refractory symptomatic vasospasm while three patients received prophylactic ITSNPT in view of the possibility of imminent clinical vasospasm </plain></SENT>
<SENT sid="2" pm="."><plain>In five patients the therapy was instituted through the intraventricular route, while in three the drug was instilled into the basal cistern </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="29321">Sodium nitroprusside</z:chebi> (SNP) was administered at an interval of 3-12 h, in varying bolus doses ranging between 2 and 5 mg depending upon the (i) mean flow velocity values on transcranial Doppler study and (ii) clinical response </plain></SENT>
<SENT sid="4" pm="."><plain>The end point of ITSNPT was either relief of vasospasm, any adverse effect or contraindication to continuation of ITSNPT </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> except one patient survived </plain></SENT>
<SENT sid="6" pm="."><plain>One patient had mild residual neurological deficit following an <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the three patients who received prophylactic ITSNPT had good outcomes </plain></SENT>
</text></document>